About
Technology
Issues
FAQ
Links
Official Page
Efficacy and safety in a 4-year follow-up of the ELEVATE-TN study comparing acalabrutinib with or without obinutuzumab versus obinutuzumab plus chlorambucil in treatment-naïve chronic lymphocytic leukemia
Distribution of the number of citations over years.
site/software ©
exaly
; All materials licenced under
CC by-SA
.